CVS to Prevent Stockpiling of Malaria Drug Amid COVID-19
March 25 (Reuters)—CVS Health said on Wednesday its pharmacy benefit management (PBM) unit was laying out measures to prevent the stockpiling of malaria drug, hydroxychloroquine, which is being tested as a potential treatment for the coronavirus. The company said it was also setting up limits on the use of azithromycin, a protease inhibitor and albuterol... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Reuters Staff Tags: Drug Updates Drug shortage HCQ Hydroxychloroquine (HCQ) Source Type: research
More News: Albuterol | Azithromycin | Coronavirus | COVID-19 | Hydroxychloroquine | Malaria | Proair HFA | Rheumatology | Ventolin | Zithromax